Association between cardiovascular health and metabolic dysfunction-associated steatotic liver disease: a nationwide cross-sectional study

Table 3 Sensitivity analysis of the association of LE8 and its subscales scores with MASLD^a

	Excluding participants with CVD history		Multiple imputation^b		CAP ≥ 263 dB/m
	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value
LE8 score
Per 10 points increase	0.69 (0.60–0.78)	< 0.001	0.68 (0.60–0.76)	< 0.001	0.66(0.59–0.73)	< 0.001
Low (0–49)	Reference		Reference		Reference
Moderate (50–79)	0.49 (0.37–0.66)	< 0.001	0.50 (0.37–0.67)	< 0.001	0.50(0.34–0.74)	0.004
High (80–100)	0.20 (0.12–0.33)	< 0.001	0.20 (0.13–0.32)	< 0.001	0.21(0.13–0.34)	< 0.001
P for trend		< 0.001		< 0.001		< 0.001
Health behaviors score
Per 10 points increase	0.95 (0.86–1.04)	0.21	0.93 (0.86–1.01)	0.07	0.92(0.84-1.00)	0.06
Low (0–49)	Reference		Reference		Reference
Moderate (50–79)	0.82 (0.65–1.05)	0.10	0.81 (0.65–0.99)	0.04	0.85(0.66–1.11)	0.19
High (80–100)	0.80 (0.49–1.31)	0.32	0.73 (0.49–1.10)	0.12	0.70(0.45–1.10)	0.10
P for trend		0.43		0.16		0.09
Health factors score
Per 10 points increase	0.64 (0.58–0.70)	< 0.001	0.64 (0.60–0.69)	< 0.001	0.63(0.58–0.68)	< 0.001
Low (0–49)	Reference		Reference		Reference
Moderate (50–79)	0.46 (0.33–0.64)	< 0.001	0.49 (0.38–0.63)	< 0.001	0.51(0.34–0.77)	0.01
High (80–100)	0.13 (0.08–0.20)	< 0.001	0.14 (0.10–0.20)	< 0.001	0.15 (0.10–0.22)	< 0.001
P for trend		< 0.001		< 0.001		< 0.001

LE8, Life’s Essential 8; MASLD, metabolic dysfunction-associated steatotic liver disease; CVD, cardiovascular disease; CAP, controlled
attenuation parameter; OR, odds ratio; CI, confidence interval
^a Adjusted for age (as a continuous variable), gender, race/ethnicity, education level, marital status, poverty income ratio (as a continuous variable), serum
alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, obesity, thyroid disease history, and sleep apnea
^b Missing data for both poverty income ratio and sleep apnea were imputed

ISSN: 2072-1315